Advertisement
Singapore markets closed
  • Straits Times Index

    3,183.61
    -33.30 (-1.04%)
     
  • S&P 500

    5,123.41
    -75.65 (-1.46%)
     
  • Dow

    37,983.24
    -475.86 (-1.24%)
     
  • Nasdaq

    16,175.09
    -267.11 (-1.62%)
     
  • Bitcoin USD

    66,028.27
    +1,695.42 (+2.64%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,984.76
    -10.82 (-0.14%)
     
  • Gold

    2,373.40
    -0.70 (-0.03%)
     
  • Crude Oil

    85.01
    -0.65 (-0.76%)
     
  • 10-Yr Bond

    4.4990
    0.0000 (0.00%)
     
  • Nikkei

    39,232.80
    -290.75 (-0.74%)
     
  • Hang Seng

    16,600.46
    -121.23 (-0.72%)
     
  • FTSE Bursa Malaysia

    1,542.53
    -8.51 (-0.55%)
     
  • Jakarta Composite Index

    7,286.88
    +32.48 (+0.45%)
     
  • PSE Index

    6,562.43
    -96.96 (-1.46%)
     

InMode Full Year 2023 Earnings: EPS Beats Expectations

InMode (NASDAQ:INMD) Full Year 2023 Results

Key Financial Results

  • Revenue: US$492.0m (up 8.3% from FY 2022).

  • Net income: US$197.9m (up 23% from FY 2022).

  • Profit margin: 40% (up from 36% in FY 2022).

  • EPS: US$2.37 (up from US$1.96 in FY 2022).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

InMode EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.4%.

Looking ahead, revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US.

ADVERTISEMENT

Performance of the American Medical Equipment industry.

The company's shares are down 5.4% from a week ago.

Risk Analysis

It is worth noting though that we have found 2 warning signs for InMode (1 is a bit concerning!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.